Celgene and Novartis Pharmaceuticals Sue Par Pharmaceutical

  • November 18, 2011

Celgene and Novartis Pharmaceuticals filed suit against Par Pharmaceutical over six patents related to drugs with diminished abuse potential.  11/10, District of New Jersey, 2:2011cv06640.


Access to the full article is currently available to RPX members only. Please contact us if you need further information.



×
×

Thank you for your feedback

×
×